The problem is, that this Otic Pharma has basically nothing to show for. Their drug candidates are only investigational. That also explains the 60/40 ownership split. But two companies that are worth nothing combined still dont amount to much. And worse than this, Ortic will use TKAI as an ATM and continually dump new shares on the market, thats why they do this transaction in the first place. Reverse merger stories are often great for trading, but I doubt that this one will be such an opportunity
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.